Promega to Co-Develop Drug-Screening Assays With Chinese Institute | GenomeWeb
NEW YORK (GenomeWeb News) — Promega and China’s Guangzhou Institute of Biomedicine and Health plan to co-develop drug-screening assays, the company said today. 
 
Under the agreement, GIBH researchers will use Promega’s drug-screening assays to develop tests for Cytochrome P450, Kinase, and GPCR profiling.
 
Promega said GIBH, which is part of the Chinese Academy of Sciences, will use the assays for their own research and will offer them through contracts to other companies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.